Sangamo Biosciences (SGMO) AI Stock Analysis

• Market Cap: $170.44M
• Dividend Yield: N/A
• Average Volume (3M): 4.96M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.12
• Revenue Growth: 565.52%
• EPS Growth: 79.44%
• Country: US
• Employees: 183
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.08
• Shares Outstanding: 301,709,470
• 10 Day Avg. Volume: 4,732,421
• 30 Day Avg. Volume: 4,960,141
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.73
• Enterprise Value/Revenue: 1.52
• Enterprise Value/Gross Profit: 1.56
• Enterprise Value/Ebitda: -2.18
• 1Y Price Target: $5.67
• Price Target Upside: 800.00% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 51 Neutral
• Price Target: $0.50 ▼(-20.63% Downside)

Sangamo Biosciences' overall stock score is primarily impacted by its challenging financial performance, which poses significant risks. While there are positive technical indicators and promising clinical developments, the financial instability and need for additional funding weigh heavily on the stock's outlook.

Positive Factors

Clinical Advancements

The positive results in the STAAR study for Fabry disease demonstrate Sangamo's capability to advance its clinical pipeline, potentially leading to accelerated FDA approval and future revenue streams.

Neurology Program Initiation

The initiation of the STAND study in chronic neuropathic pain marks a significant step in Sangamo's expansion into neurology, potentially opening new therapeutic markets and diversifying its product pipeline.

Equity Offering

The successful equity offering provides Sangamo with a financial runway into late 2025, allowing continued R&D investment and strategic flexibility while seeking a commercialization partner.

Negative Factors

Financial Instability

Ongoing negative cash flows and declining revenue highlight financial instability, which could hinder Sangamo's ability to sustain operations and invest in R&D without additional funding.

Balance Sheet Weakness

The weakening balance sheet, characterized by a declining equity base and increased leverage, poses significant financial risks, potentially limiting Sangamo's ability to secure favorable financing terms.

Need for Additional Funding

The need for additional funding underscores Sangamo's financial challenges, which may affect its ability to advance its pipeline and achieve strategic goals without diluting shareholder value.

Sangamo Biosciences Business Overview & Revenue Model

Company Description

Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.

How the Company Makes Money

Sangamo generates revenue through a combination of collaborations, licensing agreements, and funding from governmental grants and private investments. Key revenue streams include milestone payments and royalties from partnerships with major pharmaceutical companies, such as Pfizer and Biogen, in which Sangamo provides its gene editing technology for the development of novel therapies. Additionally, the company may receive upfront payments in collaboration agreements, as well as potential future earnings tied to the successful commercialization of partnered products. Sangamo also engages in research grants and funding opportunities to support its R&D efforts, further contributing to its overall revenue.

Sangamo Biosciences Financial Statement Overview

Summary

Sangamo Biosciences is facing significant financial challenges, including declining revenue, negative profitability, a weakening balance sheet with increased leverage, and persistent negative cash flows. These factors indicate financial instability and increased operational risks.

Income Statement

Sangamo Biosciences has shown significant volatility in its revenue and profitability metrics. There has been a substantial decline in total revenue from $176.23M in 2023 to $57.8M in 2024, representing a negative revenue growth trend. Gross profit margins have been inconsistent, and the company consistently reports negative EBIT and net income margins, indicating ongoing operational and profitability challenges.

Balance Sheet

The balance sheet reflects a strained financial position with a declining equity base, from $82.89M in 2023 to $22.77M in 2024. The debt-to-equity ratio has worsened due to reduced equity, suggesting increased leverage. The equity ratio declined significantly, indicating reduced shareholder equity relative to total assets, potentially increasing financial risk.

Cash Flow

The cash flow statements highlight persistent negative free cash flow, with a slight improvement from -$246M in 2023 to -$67.4M in 2024. Operating cash flow has remained negative, raising concerns about the company's ability to generate cash from operations. The free cash flow to net income ratio remains unfavorable, reflecting poor cash conversion.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	81.71M	57.80M	176.23M	111.30M	110.70M	118.19M
Gross Profit	79.58M	57.80M	154.04M	99.19M	101.26M	-62.45M
EBITDA	-56.86M	-89.09M	-240.71M	-189.17M	-173.90M	-123.87M
Net Income	-63.31M	-97.94M	-257.83M	-192.28M	-178.30M	-121.12M
Balance Sheet
Total Assets	97.56M	101.64M	165.32M	562.51M	721.92M	938.55M
Cash, Cash Equivalents and Short-Term Investments	38.34M	41.92M	81.00M	277.63M	376.55M	641.42M
Total Debt	23.46M	30.57M	38.10M	43.11M	48.08M	42.09M
Total Liabilities	77.96M	78.86M	82.43M	267.55M	346.58M	441.18M
Stockholders Equity	19.60M	22.77M	82.89M	294.96M	375.34M	497.37M
Cash Flow
Free Cash Flow	-36.19M	-67.41M	-246.00M	-243.80M	-256.53M	155.16M
Operating Cash Flow	-35.90M	-67.14M	-224.84M	-223.63M	-233.25M	169.88M
Investing Cash Flow	1.53M	37.52M	153.53M	59.28M	248.20M	-271.63M
Financing Cash Flow	43.54M	28.38M	14.59M	84.66M	32.86M	153.10M

Sangamo Biosciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.63
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SGMO, the sentiment is Positive. The current price of 0.63 is above the 20-day moving average (MA) of 0.53, above the 50-day MA of 0.54, and below the 200-day MA of 0.85, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 66.85 is Neutral, neither overbought nor oversold. The STOCH value of 71.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SGMO.

Sangamo Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FDMT	52 Neutral	394.17M	-2.27	-31.51%	―	―	―
SGMO	51 Neutral	$170.44M	―	-298.41%	―	565.52%	79.44%
IKT	46 Neutral	128.17M	-1.42	―	―	-100.00%	62.82%
TERN	45 Neutral	688.71M	-7.12	―	―	―	20.37%
ANNX	38 Underperform	309.88M	-2.17	―	―	―	-5.57%
ELTX	30 Underperform	180.54M	-2.60	―	―	―	-4.60%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Sangamo Biosciences Corporate Events

Sangamo Biosciences Reveals Promising Fabry Disease Study Results

On September 4, 2025, Sangamo Therapeutics announced updated clinical data from its Phase 1/2 STAAR study of isaralgagene civaparvovec, a gene therapy for Fabry disease, presented at ICIEM2025 in Kyoto. The study showed promising results, with patients demonstrating stable cardiac function and significant improvements in disease severity and quality of life. The company is preparing a Biologics License Application for accelerated approval, targeting submission in early 2026, contingent on securing additional funding. These developments could enhance Sangamo’s position in the gene therapy market and offer new treatment options for Fabry disease patients.

Sangamo Announces Positive Results for Fabry Disease Therapy

On June 24, 2025, Sangamo Therapeutics, Inc. announced positive topline results from its Phase 1/2 STAAR study of isaralgagene civaparvovec, a gene therapy for Fabry disease. The study showed significant improvements in kidney function and quality of life measures, with a favorable safety profile. These results support the potential of isaralgagene civaparvovec as a one-time treatment for Fabry disease, paving the way for a Biologics Licensing Application under the Accelerated Approval pathway by early 2026.

Sangamo Biosciences Approves Amendments to Equity Plan

On June 12, 2025, Sangamo Therapeutics, Inc. held its annual meeting where stockholders approved significant amendments to the 2018 Equity Incentive Plan. This included increasing the number of shares available for issuance and the number of shares for incentive stock options. The meeting also saw the election of directors, approval of executive compensation, and ratification of Ernst & Young LLP as the company’s independent auditor. These decisions reflect Sangamo’s strategic focus on expanding its equity incentives to attract and retain talent, which could enhance its competitive position in the biotech industry.